Please provide your email address to receive an email when new articles are posted on . Outcomes may vary among different fixed-dose combination inhalers for COPD ...
QUANTIFY study met primary endpoint demonstrating non-inferiority of Ultibro®Breezhaler® vs tiotropium 18 mcg plus formoterol 12 mcg in improving health-related quality of life outcomes[1],[2] ...
Background: Long-acting beta-agonist (LABA) plus long-acting muscarinic antagonist (LAMA) is superior to monotherapy or corticosteroid/LABA in terms of improving lung function, alleviating symptoms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results